Synthesis of (E)-8-(3-Chlorostyryl)caffeine Analogues Leading to 9-Deazaxanthine Derivatives as Dual A2A Antagonists/MAO-B Inhibitors

被引:47
作者
Rivara, Silvia [1 ]
Piersanti, Giovanni [2 ]
Bartoccini, Francesca [2 ]
Diamantini, Giuseppe [2 ]
Pala, Daniele [1 ]
Riccioni, Teresa [3 ]
Stasi, Maria Antonietta [3 ]
Cabri, Walter [3 ]
Borsini, Franco [3 ]
Mor, Marco [1 ]
Tarzia, Giorgio [2 ]
Minetti, Patrizia [3 ]
机构
[1] Univ Parma, Dipartimento Farm, I-43124 Parma, Italy
[2] Univ Urbino, Dept Biomol Sci, I-61029 Urbino, PU, Italy
[3] Sigma Tau Ind Farmaceut Riunite SpA, I-00040 Pomezia, Italy
关键词
ADENOSINE RECEPTOR ANTAGONISTS; MONOAMINE-OXIDASE-B; PARKINSONS-DISEASE; ARYL IODIDES; COUPLING REACTIONS; CROSS-COUPLINGS; SCH; 58261; C-C; POTENT; ST1535;
D O I
10.1021/jm301686s
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A systematic modification of the caffeinyl core and substituents of the reference compound (E)-8-(3-chlorostyryl)caffeine led to the 9-deazaxanthine derivative (E)-6-(4-chlorostyryl)-1,3,5,=trimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4-(3H,5H)-dione (17f), which acts as a dual human A(2a) antagonist/MAO-B inhibitor (K-i(A(2A)) = 260 nM; IC50(MAO-B) = 200 nM; IC50(MAO-A) = 10 mu M) and dose dependently counteracts haloperidol-induced catalepsy in mice from 30 mg/kg by the oral route. The compound is the best balanced A(2A) antagonist/MAO-B inhibitor reported to date, and it could be considered as a new lead in the field of anti-Parkinson's agents. A number of analogues of 17f were synthesized and qualitative SARs are discussed. Two analogues of 17f, namely 18b and 19a, inhibit MAO-B with IC50 of 68 and 48 nM, respectively, being 5-7-fold more potent than the prototypical MAO-B inhibitor deprenyl (IC50 = 334 nM).
引用
收藏
页码:1247 / 1261
页数:15
相关论文
共 88 条
[1]   Efficient one-pot synthesis of 1-aryl 1,2,3-triazoles from aryl halides and terminal alkynes in the presence of sodium azide [J].
Andersen, J ;
Bolvig, S ;
Liang, XF .
SYNLETT, 2005, (19) :2941-2947
[2]  
[Anonymous], 2011, MAESTR VERS 9 2
[3]  
[Anonymous], 2011, PRIM VERS 3 0
[4]  
[Anonymous], 2011, GLID VERS 5 7
[5]  
[Anonymous], 2011, MACR VERS 9 9
[6]   CSC, an adenosine A2A receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alteration in the 6-OHDA-lesioned rats [J].
Aquiar, Lissiana My. ;
Macedo, Danielle S. ;
Vasconcelos, Silvania M. M. ;
Oliveira, Aline A. ;
Clea, F. ;
de Sousa, F. ;
Viana, Glauce S. B. .
BRAIN RESEARCH, 2008, 1191 :192-199
[7]   Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease [J].
Armentero, Marie Therese ;
Pinna, Annalisa ;
Ferre, Sergi ;
Luis Lanciego, Jose ;
Mueller, Christa E. ;
Franco, Rafael .
PHARMACOLOGY & THERAPEUTICS, 2011, 132 (03) :280-299
[8]   Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidines as new A2A and A3 adenosine receptors antagonists [J].
Baraldi, PG ;
Fruttarolo, F ;
Tabrizi, MA ;
Preti, D ;
Romagnoli, R ;
El-Kashef, H ;
Moorman, A ;
Varani, K ;
Gessi, S ;
Merighi, S ;
Borea, PA .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (07) :1229-1241
[9]   SYNTHESIS OF NEW PYRAZOLO[4,3-E]1,2,4-TRIAZOLO[1,5-C] PYRIMIDINE AND 1,2,3-TRIAZOLO[4,5-E]1,2,4-TRIAZOLO[1,5-C] PYRIMIDINE DISPLAYING POTENT AND SELECTIVE ACTIVITY AS A(2A) ADENOSINE RECEPTOR ANTAGONISTS [J].
BARALDI, PG ;
MANFREDINI, S ;
SIMONI, D ;
ZAPPATERRA, L ;
ZOCCHI, C ;
DIONISOTTI, S ;
ONGINI, E .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (21) :2539-2544
[10]   Divergent synthesis of novel 9-deazaxanthine derivatives via late-stage cross-coupling reactions [J].
Bartoccini, Francesca ;
Piersanti, Giovanni ;
Mor, Marco ;
Tarzia, Giorgio ;
Minetti, Patrizia ;
Cabri, Walter .
ORGANIC & BIOMOLECULAR CHEMISTRY, 2012, 10 (44) :8860-8867